

SCIENTIFIC PRESENTATIONS:

Relevance of Using International Real-World Data in Regulatory and HTA Decision Making. A Jaksa, RH Ben-Joseph, K Chan, P. Jonsson. ISPOR 2022 May 18. https://www.ispor.org/docs/default-source/intl2022/ispor-2022-panel-relevance-of-international-data-1.pdf?sfvrsn=a2d3e53d_0

Lurbinectedin versus an External Control Arm in Patients with Small Cell Lung Cancer. Apar Ganti, Trisha Prince, Xue Wang, Adina Estrin, Anne Boccuti, Badri Rengarajan, Navit Naveh, Ralph D'Agostino Jr., Trevor Alvord, Rami Ben-Joseph. North America Conference on Lung Cancer (NACLC 2022), September 23-25, 2022 Chicago, IL.

Characterization of Real World Use of Lurbinectedin in Adult Patients with Small Cell Lung Cancer in the United States. Xue Wang, Badri Rengarajan, Wenyan Li, Patricia Prince, Julie Paone, Neloufar Rahai, Anne Boccuti, Cristina Baratta, Tianyi Lu, Yanyan Cao, Apar Ganti, Ralph D'Agostino Jr, Rami Ben-Joseph. IASLC World Conference on Lung Cancer (WCLC 2022) August 6-9, 2022, Vienna, Austria.

Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin. 2022 European Society of Medical Oncology. A. Estrin, X. Wang, A. Boccuti, P. Prince, N. Gautam, B. Rengarajan, W. Li, T. Lu, Y. Cao, N. Naveh, R. D'Agostino, R. Ben-Joseph, A.K. Ganti. European Society of Medical Oncology (ESMO) Congress 2022 Paris France.

Efficacy of lurbinectedin in a clinical trial versus other standard of care in a real-world comparator arm in relapsed/refractory small cell lung cancer patients. Apar Kishor Ganti, Patricia Prince, Xue Wang, Adina Estrin, Anne Boccuti, Badri Rengarajan, Navit Naveh, Ralph D'Agostino Jr., Trevor Alvord, and Rami Ben-Joseph. ASCO 2022. Journal of Clinical Oncology 2022 40:16_suppl, e20619-e20619 <https://meetings.asco.org/abstracts-presentations/208920>

Overall survival throughout treatment course among patients diagnosed with small cell lung cancer. Adina Estrin, Patricia Prince, Dylan Supina, Rami H. Ben-Joseph, Anne Boccuti, Kobby Asubonteng, Moshe Fridman, Badri Rengarajan, Raj Hanvesakul, Ben Taylor. 2021 ASCO Annual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr e20576). https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.e20577

Treatment patterns and characteristics in the second and third-line therapy setting for real-world small cell lung cancer patients. Patricia Prince, Adina Estrin, Dylan Supina, Rami Ben-Joseph, Anne Boccuti, Kobby Asubonteng, Badri Rengarajan, Moshe Fridman, Raj Hanvesakul, Benjamin Taylor. 2021 ASCO Annual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr e20576). https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.e20576

Hypertension Onset Among Narcolepsy Patients Newly Treated with High Sodium Oxybate. Rami H. Ben-Joseph, Virend K. Somers, Jed Black, Ralph B. D'Agostino, Ragy Saad, Mat Davis, Wayne Macfadden, Katherine E. Mues, Clark Jackson, Weiyi Ni, Michael N. Cook, Julia Pitino, Helen Latimer, Elizabeth C. Dabrowski, William B. White. American Neurological Association (ANA 2022). Poster Number: M297
Session Date/Time: Monday, October 24, 2022 Chicago

Hypertension Onset Among Patients With Narcolepsy Newly Treated With Sodium Oxybate. Rami H. Ben-Joseph, Virend K. Somers, Jed Black, Ralph B. D'Agostino, Ragy Saad, Mat Davis, Wayne Macfadden, Katherine E. Mues, Clark Jackson, Weiyi Ni, Michael N. Cook, Julia Pitino, Helen Latimer, Elizabeth C. Dabrowski, William B. White. 2022 35th annual Psych Congress. September 18 from 1:30-3:00PM & Monday, September 19 from 1:30P-3: 22, New Orleans, LA

Hypertension Onset Among Narcolepsy Patients Newly Treated with High Sodium Oxybate. Rami H. Ben-Joseph, Virend K. Somers, Jed Black, Ralph B. D'Agostino, Jr., Ragy Saad, Mat Davis, Wayne Macfadden, Katherine E. Mues, Clark Jackson, Weiyi Ni, Michael N. Cook, Julia Pitino, Helen Latimer, Elizabeth C. Dabrowski, William B. White. Sleep 2022, American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS) Poster ID: LBA062 Charlotte, North Carolina on June 4-8, 2022.

Podium presentation: Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a Real-World Evidence Study. Rami H. Ben-Joseph, Ragy Saad, Jed Black, Elizabeth C. Dabrowski, Ben Taylor, Sophia Gallucci Virend K. Somers. 2022 American Association of Neurology (AAN) Annual Meeting April 2-7, Seattle, WA April 3 2022.

CardioVascular Burden Of Narcolepsy Disease (CV-BOND): A Real-World Evidence Study. R.H. Ben-Joseph; R. Saad; J. Black; E.C. Dabrowski; B. Taylor; S. Gallucci; V.K. Somers. 2022 World Sleep Tuesday, March 15, 6:15pm - 7:00pm

Utilization of Diagnostic Sleep Testing Prior to Idiopathic Hypersomnia Diagnosis Among US Adults: A Real-World Claims Analysis. Ragy Saad, Rami H. Ben-Joseph, Patricia Prince, Catharine Stack, Shay Bujanover, Ben Taylor. Presented at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS) Virtual Meeting, June 10-13, 2021.

Clinical Presentation Prior to Idiopathic Hypersomnia Diagnosis Among US Adults: A Retrospective, Real-World Claims Analysis. Ragy Saad, Rami H. Ben-Joseph, Patricia Prince, Catharine Stack, Shay Bujanover, Ben Taylor. Presented at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS) Virtual Meeting, June 10-13, 2021.

Cardiovascular Burden of Narcolepsy Disease (CV-BOND): A Real-World Evidence Study. Rami H. Ben-Joseph, Ragy Saad, Elizabeth C. Dabrowski, Ben Taylor, Sophia Gallucci, Virend K. Somers. 2021. Sleep, Volume 44, Issue Supplement_2, May 2021, Page A198. Presented at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS) Virtual Meeting, June 10-13, <https://doi.org/10.1093/sleep/zsab072.502>

Podium Presentation: Treatment of day surgery patients with multiple injectable opioids: frequency and relationship with total charges and 30 day readmissions. Chingcuanco F, Divino V, DeKoven M, Gordon R, Meier A, and Ben-Joseph R. Presented at PAINWeek 2017, September 5-10, 2017. Las Vegas, NV.

Podium Presentation: Study design considerations for value demonstration in pain: Real world case studies. Ben-Joseph R. Presented at PAINWeek 2017, September 5-10, 2017. Las Vegas, NV.

The treatment of patients with multiple injectable opioids on the day of surgery in the outpatient setting: frequency and relationship with total hospital charge and 30-day readmissions. Chingcuanco F, Divino V, DeKoven M, Gordon R, Meier A, and Ben-Joseph R. Presented at PAINWeek 2017. September 5-10, 2017 Las Vegas, NV.

The treatment of patients with multiple injectable opioids on the day of surgery in the inpatient setting: frequency and relationship with total hospital charge. Chingcuanco F, Divino V, DeKoven M, Gordon R, Meier A, and Ben-Joseph R. Presented at PAINWeek 2017, September 5-10, 2017. Las Vegas, NV.

The impact of respiratory depression following planned inpatient surgeries on hospital resource utilization and charges across the united states. Ben-Joseph R., Meier A, Chingcuanco F, Zhao S, Ni W, Divino V, Dekoven M, Gordon R. Presented at the ISPOR 22nd Annual International Meeting. May 20-24, 2017. Boston, MA.

The treatment of patients with injectable opioids for uncontrolled postoperative pain in the inpatient setting: incidence and impact on hospital charges. Chingcuanco F, Divino V, DeKoven M, Gordon R, Meier A, and Ben-Joseph R. Presented at the ISPOR 22nd Annual International Meeting. May 20-24, 2017. Boston, MA.

Incidence of respiratory depression following inpatient surgery. Ben-Joseph R, Meier A, Chingcuanco F, Ni W, Divino V, Dekoven M, Gordon R. Presented at the AUA 64th Annual Meeting. May 4-5, 2017. Washington, DC.

Incidence of respiratory depression following inpatient surgery. Ben-Joseph R, Meier A, Chingcuanco F, Ni W, Divino V, Dekoven M, Gordon R. Presented at the IARS 2017 Annual Meeting. May 6-9, 2017. Washington, DC.

Incidence of patients treated with injectable opioids for uncontrolled postoperative pain in the inpatient setting. Chingcuanco, F, Divino, V, DeKoven, M, Gordon, R, Meier, Angela., and Ben-Joseph, R. Presented at the 13th Annual Perioperative Medicine Summit; March 8-11, 2017. Fort Lauderdale, FL.

A retrospective identification of venous thromboembolism events peri-operatively using claims-based data. Sepassi A, Chingcuanco F, Ni W, Ben-Joseph R. Presented at the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017. March 27-30, 2017. Denver, CO.

Prevalence of diagnosed opioid abuse in patients prescribed immediate release hydrocodone in the United States. Accepted for presentation at the 2015 International Conference on Opioids. June 7-9, 2015 Boston, MA

Rates of diagnosed opioid abuse among patients with chronic use of immediate-release opioids. Accepted for presentation at the 2015 International Conference on Opioids. June 7-9, 2015 Boston, MA

Direct healthcare costs of opioid abuse in patients prescribed immediate release hydrocodone in the United States. Accepted for presentation at the 2015 ISPOR Annual International Meeting. May 18-20, 2015 Philadelphia, PA

Treatment patterns among chronic users of immediate-release oxycodone initiating treatment with extended-release opioids. Accepted for presentation at the 2015 ISPOR Annual International Meeting. May 18-20, 2015 Philadelphia, PA

Feasibility of using the SF-36 health survey to screen for risk of major depressive disorder. Accepted for presentation at the 2015 ISPOR Annual International Meeting. May 18-20, Philadelphia, PA

Extended release opioid treatment patterns following initiation of immediate release hydrocodone. Burgoyne D, Brixner D, Kansal A, Paramore C, Chitnis A, Bell J, Holly P, Ben-Joseph R. Presented at the 2015 AMCP 27th Annual Meeting, April 7-10, San Diego, CA

Characterizing healthcare resource utilization and costs following patterns of immediate release hydrocodone use. Wild H, Kansal A, Chitnis A, Bell J, Holly P, Boulanger L, Ben-Joseph R. Presented at the 2015 AMCP 27th Annual Meeting, April 7-10, San Diego, CA (awarded silver medal)

Pill burden, healthcare resource utilization and costs among subpopulations of immediate release hydrocodone users. Ben-Joseph R, Yang S, Yang E, Holly P, Boulanger L. Presented at the 2014 ISPOR 17th Annual European Congress; November 8-14, 2014; Amsterdam, The Netherlands

Rates of diagnosed opioid abuse and incremental direct healthcare costs among patients with use of immediate-release hydrocodone. Ben-Joseph R, Yang E, Huse S; Bhagnani T; Holly P; Kansal A. Presented at the 2014 ISPOR 17th Annual European Congress; November 8-14, 2014; Amsterdam, The Netherlands

Examining the use of ICD-9-CM diagnosis codes for opioid abuse and opioid dependence in commercial claims data. Shei A, Rice B, Kirson NY, Bodnar K, Cummings A, Birnbaum H, Holly P, Ben-Joseph R. Presented at the Research and Evidence Podium Session at: 2014 AMCP NEXUS; Oct 7-10, 2014; Boston, MA. (awarded platinum Medal)

Opioid-induced constipation: Effects on patient adherence to treatment and economic burden. Wissinger E, Lindsay P, Holly P, Paramore L, Ben-Joseph R. Presented at the 2014 ASPMN 24th National Conference; Sept 17-21, 2014; San Diego, CA

Comparing the prevalence and healthcare costs of diagnosed opioid abuse among commercially-insured beneficiaries using two distinct commercial claims databases. Rice B, Kirson NY, Shei a, Enloe CJ, Cummings AK, Bodnar K, Birnbaum HG, Holly, P, Ben-Joseph R. Presented at the 2014 PAINWeek; September 2-5, 2014; Las Vegas, NV

Methods to estimate the prevalence and healthcare costs of undiagnosed opioid abuse among commercially-insured individuals. Shei A, Rice B, Kirson NY, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R. Presented at the 2014 PAINWeek; September 2-5, 2014; Las Vegas, NV

Medical resource use and costs among pain patients with potential opioid tolerability issues. NY, Shei A, Kirson NY, Birnbaum HG, Holly P, Ben-Joseph R, Michna E. Presented at the 2014 International Conference on Opioids; June 8-10, 2014; Boston, MA

Consequences of patient access restrictions to branded hydrochloride controlled release on healthcare utilization and costs a case control study of US health plans Rami Ben-Joseph, Chi-Chang Chen, Ajita P. De, Rolin L. Wade, Dhvani Shah. Presented at the 2014 ISPOR 19TH Annual International Meeting; May 31–June 4, Montreal, QC, CANADA

Differences between high-cost and low-cost patients diagnosed with opioid abuse. Rice B, Kirson NY, Bodnar K, Shei A, Birnbaum HG, Holly P, Ben-Joseph R. Presented at the 2014 ISPOR 19TH Annual International Meeting; May 31–June 4, Montreal, QC, CANADA

The burden of opioid abuse among commercially-insured patients. Rice JB, Kirson NY, Shei A, Enloe C, Cummings AK, Birnbaum HG, Ben-Joseph R. Presented at: Presented at the 2014 ISPOR 19TH Annual International Meeting; May 31–June 4, Montreal, QC, CANADA (awarded bestposter presentation)

Estimating the prevalence and healthcare costs of diagnosed opioid abuse in a large commercial claims database. Rice, B, Kirson, NY, Shei, A., Enloe, C., Cummings, AK, Birnbaum, H., Ben-Joseph, R. Presented at the 2014 AMCP, Tampa, FL April 1-4

Opioid utilization and abuse rates following the introduction of an abuse-deterrent formulation Michna, E., Kirson, NY, Shei, A., Birnbaum, HA, Ben-Joseph, R. Presented at the 2014 AMCP, Tampa, FL April 1-4 (awarded silver medal)

Characteristics of high -cost patients diagnosed with opioid abuse. Rice, B, Kirson, NY, hei, A., Birnbaum, H, Holly, P, Ben-Joseph, R. Presented at the 2014 AMCP, Tampa, FL April 1-4 (awarded bronze medal)

The epidemiology of opioid-acetaminophen combinations exposure and acetaminophen toxicity in the United States. Blieden, M, Paramore C.L., Shah, D., Ben-Joseph, R. Presented at the 2014 AMCP, Tampa, FL April 1-4 (awarded bronze medal)

Treatment patterns among those who experience middle-of-the-night (motn) awakening. Moline M, Brown D, DiBonaventura M, Lorenzo R, Shah D, BenJoseph R. Presented at the 5th World Congress on Sleep Medicine. September 28 – October 2, 2013. Valencia, Spain

The association of middle-of-the-night awakening (motn) with quality of life and work productivity among patients with/ without psychiatric disorders. Moline M, DiBonaventura M, Shah D, Bell J, BenJoseph R. Presented at the ISOQOL 20th Annual Conference. October 9-12, 2013. Miami, FL

Hidden costs to employers of opioid abuse – healthcare costs, work- loss costs, and prevalence of opioid abuse among commercially-insured beneficiaries. Rice, B., Kirson, NY., Cummings, AK., Bodnar, K, Birnbaum, H, Ben-Joseph, R. Presented at the 2013 PainWeek - The National Conference on Pain for Frontline Practitioners. September 4-7. Las Vegas, NV

The impact of an abuse-deterrent formulation of an extended-release opioid on healthcare utilization and costs. Rossiter, L., Rice, B., Kirson, NY, Shei, A., Kaminsky, M. Birnbaum, H., Ben-Joseph, R. Presented at the 2013 PainWeek - The National Conference on Pain for Frontline Practitioners September 4-7. Las Vegas, NV

Consequences of oxycontin patient access restrictions on healthcare utilization and costs. BenJoseph R, Chen C, De A, Wade R, Shah D. Podium presentation and poster presentation at 2013 PainWeek - The National Conference on Pain for Frontline Practitioners. September 4-7, 2013. Las Vegas, NV

Estimating the Societal Economic Impact of the Abuse-Deterrent Formulations of Long Acting Opioids in the U.S., Rossiter, L.F, Kirson, N, Shei, A, White, A.G, Birnbaum, H, Ben-Joseph, R, Michna, E. Presented at the 2013 Academy Health Annual Research Meeting (ARM) June 23-25. Baltimore, MD

The prevalence of middle-of-the-night awakening (MOTN) among those with chronic comorbidities in the United States, Moline, M, DiBonaventura, M, Shah, D, Ben-Joseph, R. Presented at 2013 American Academy of Sleep Medicine. June 1-5. Baltimore, MD

The direct and indirect costs associated with middle-of-the-night (MOTN) awakening: a matched-case control analysis. DiBonaventura, M, Moline, M, Ben-Joseph, R, Shah, D. Presented at the 2013 American Academy of Sleep Medicine. June 1-5. Baltimore, MD

Costs associated with those diagnosed, undiagnosed, and unaware of their middle-of-the-night (MOTN) awakening. Ben-Joseph, R, DiBonaventura, M, Shah, D, Moline, M. Presented at the 2013 American Academy of Sleep Medicine. June 1-5. Baltimore, MD

The health status and activity impairment burden associated with middle-of-the-night awakening (MOTN): a matched-case control analysis. DiBonaventura, M, Moline, M, Ben-Joseph, R, Shah, D. Presented at the 2013 American Academy of Sleep Medicine. June 1-5. Baltimore, MD

The relationship between symptom frequency and health outcomes among those who experience middle-of-the-night (MOTN) awakening at least once a week. Moline, M, DiBonaventura, M, Ben-Joseph, R, Shah, D. Presented at the 2013 American Academy of Sleep Medicine. June 1-5. Baltimore, MD

Prevalence and treatment patterns of those diagnosed, undiagnosed, and unaware of their middle-of-the-night awakening (MOTN). Ben-Joseph, R, DiBonaventura, M, Shah, D, Moline, M. Presented at the 2013 American Academy of Sleep Medicine. June 1-5. Baltimore, MD

Impact of dosage strength on medication persistence among patients treated with buprenorphine transdermal system. Pergolizzi, JV, Ben-Joseph, R, Chang, C, Pierz, K, Shah, D, Hess, G. Presented at the 2013 International Society for Pharmacoeconomics and Outcomes Research, May 18-22, New Orleans, LA

Factors predicting medication persistence among patients initiating buprenorphine transdermal system. Pergolizzi, JV, Hess, G, Chun-Lan, C, Shah, D, Pierz, K, Ben-Joseph, R. Presented at the 2013 International Society for Pharmacoeconomics and Outcomes Research, May 18-22, New Orleans, LA

Dosing of patients newly treated with Butrans® (buprenorphine transdermal system). Pergolizzi, JV, Hess, G, Ben-Joseph, R, Chun-Lan, C, Pierz, K. Presented at the 2013 American Pain Society's 32nd Annual Scientific Meeting, May 8-11, New Orleans, LA

Utilization of central muscle relaxants (CMRs) in patients initiating Butrans® (buprenorphine transdermal system). Pergolizzi, JV, Hess, G, Chang, C, Ben-Joseph, R, Pierz, K. Presented at the 2013 American Pain Society's 32nd Annual Scientific Meeting, May 8-11, New Orleans, LA

Estimating the payer-specific excess medical costs of opioid abuse in the U.S. Michna, E, Kirson, N, Shei, A, White, A.G, Birnbaum, H, Ben-Joseph, R, Rossiter, L.F. Presented at the 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting. May 18-22, New Orleans, LA

Prevalence of CYP450 drug-drug exposures (DDE) among oxycodone CR patients. Pergolizzi JV, Labhsetwar SA, Summers KH, Puenpatom RA, Ma L, Ben-Joseph R. Presented at 2011 PAINWeek, September 7-10, Las Vegas NV

Average daily average consumption (DACon) between Oxycodone CR and Oxymorphone ER before and after the introduction of the new formulation of Oxycodone CR. Summers KH, Puenpatom RA, Garvin R, Ma L, Szeinbach SL, Ben-Joseph R. Presented at 2011 PAINWeek, September 7-10, Las Vegas NV

Direct and indirect costs of privately-insured patients treated with oxymorphone extended-release or oxycodone controlled-release tablets. Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Ben-Joseph RH, Berner T, Summers KH. Presented at the 2011 International Society for Pharmacoeconomics and

Outcomes Research 16th Annual International Meeting. May 21-25, Baltimore MD

Economic impact of potential drug-drug interactions among patients taking opioids. Summers KH, Puenpatom RA, Ohsfeldt RR, Rajan N, Ben-Joseph RH. Presented at the 2011 International Society for Pharmacoeconomics and Outcomes Research 16th Annual International Meeting. May 21-25, Baltimore MD

A comparison of daily average supply (dasup) of oxycodone and oxymorphone long-acting oral tablets. Rubino MJ, Summers KH, Puenpatom RA, Fu C, Ohsfeldt RR, Ben-Joseph RH. Presented at the 2011 International Society for Pharmacoeconomics and Outcomes Research 16th Annual International Meeting. May 21-25, Baltimore MD

Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pergolizzi JV, Labhsetwar SA, Puenpatom RA, Ben-Joseph RH, Summers KH. Presented at the 2011 American Pain Society's 30th Annual Scientific Meeting. May 19-21, Austin TX

Mental health and physical function responses to opioid therapy for chronic noncancer pain over 1 year: data from the opioid utilization study. Stanos SP, Irving GA, Argoff CE, Puenpatom RA, Gould EM, OPUS Group. Presented at the 2010 American Osteopathic Association Osteopathic Medical Conference & Exposition. October 24-28, San Francisco CA

Impact on pharmacy costs of differences in daily average consumption of oxymorphone extended-release and oxycodone controlled-release tablets by low back pain and/or osteoarthritis patients in a commercially insured population. Thomson H, Hertry A, Berner T, Puenpatom RA. Presented at the 2010 Academy of Managed Care Pharmacy Educational Conference. October 13-15, St. Louis MO

Psychometric characteristics of patients prescribed chronic opioid therapy for chronic noncancer pain: data from the opioid utilization study (OPUS). Stanos SP, Argoff CE, Irving GA, Puenpatom RA, Zhao S, Gould EM, OPUS Group. Presented at the 2010 American Academy of Pain Management. September 21-24, Las Vegas NV

Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pergolizzi JV, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH. Presented at the 2010 Pain Week. September 8-11, Las Vegas NV

Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with osteoarthritis. Pergolizzi JV, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH. Presented at the 2010 Pain Week. September 8-11, Las Vegas NV

Long-term stability of mental health and physical function in patients prescribed opioid therapy for chronic noncancer pain: data from the opioid utilization study. Argoff CE, Stanos SP, Irving GA, Puenpatom RA, Gould EM. Presented at the 2010 World Congress on Pain. August 28-September 2, Montreal QC, Canada

Daily average consumption analysis of low back pain and osteoarthritis patients using oxymorphone extended-release and oxycodone hydrochloride controlled-release tablets in a commercially insured population. Berner T, Puenpatom RA, Lai PC, Thomson H, Hartry A. Presented at the 2010 International Society for Pharmacoeconomics and Outcomes Research 15th Annual International Meeting. May 15-19, Atlanta GA

Descriptive profile of Medicaid patients with postherpetic neuralgia treated and untreated with lidocaine patch 5%. Kirson NY, Puenpatom RA, Icanoca JI, Birnbaum HG, Wei R, Schiller M, Summers KH. Presented at the 2010 American Pain Society 29th Annual Scientific Meeting. May 6-8, Baltimore MD

Demographic characteristics of patients prescribed chronic opioid therapy for chronic noncancer pain: data from the opioid utilization study (OPUS). Stanos SP, Argoff CE, Irving GA, Puenpatom RA, Zhao S, Gould EM, OPUS Group. Presented at the 2010 American Pain Society 29th Annual Scientific Meeting. May 6-8, Baltimore MD

Psychometric characteristics of patients prescribed chronic opioid therapy for chronic noncancer pain: data from the opioid utilization study (OPUS). Stanos SP, Argoff CE, Irving GA, Puenpatom RA, Zhao S, Gould EM, OPUS Group. Presented at the 2010 American Pain Society 29th Annual Scientific Meeting. May 6-8, Baltimore MD

Pain characteristics of patients prescribed chronic opioid therapy for chronic noncancer pain: data from the opioid utilization study (OPUS). Stanos SP, Argoff CE, Irving GA, Puenpatom RA, Zhao S, Gould EM, OPUS Group. Presented at the 2010 American Pain Society 29th Annual Scientific Meeting. May 6-8, Baltimore MD

Economic value of lidocaine patch 5% vs. gabapentin or pregabalin in Medicaid patients with postherpetic neuralgia. Ivanova J, Puenpatom RA, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers KH. Presented at the 2010 AMCPs 22nd Annual Meeting & Showcase. April 7-10, San Diego CA

The direct and indirect costs of obesity in an employed population. Durden E; Ben-Joseph R, Hugh D. Presented at the 2008 International Society for Pharmacoeconomics and Outcomes Research 13th Annual International Meeting. May, Toronto, Canada

Projected Cost of Cardiometabolic Risk Factors in Commercially Insured Normal and Overweight Primary Care Patients. Sameer R. Ghate¹, Qayyim Said, Dan Huse, Rami Ben-Joseph, Diana I. Brixner. Presented at the 2008 International Society for Pharmacoeconomics and Outcomes Research 13th Annual International Meeting. May, Toronto, Canada

Cardiometabolic risk and healthcare utilization for Hispanic and non-Hispanic female health plan members. Sarah J Beaton, Scott B Robinson, Ann Von Worley, Herbert T Davis, Audra Boscoe, Rami Ben-Joseph, Lynn J Okamoto. Presented at the 2008 HMO Research Network conference. April, Minneapolis MN

Cardiometabolic risk factors and healthcare cost for a sample of health plan members. Eaton SJ, Robinson SB, Worley AV, Davis HT, Boscoe A, Ben-Joseph R, Okamoto LJ. Presented at the 2007 American Public Health Association. Nov 3-7, Washington DC

Effects of comorbid conditions among the overweight/obese on work productivity loss and activity impairment. Kannan H, Thompson S, Bolge SC. Presented at the 2007 10th ISPOR Annual European Congress. October 20-23, Dublin Ireland

The NO LIMITS (New Options and Lifestyle Intervention for the Metabolic Syndrome) trial: methods and baseline characteristics. Miner, Denin, Leslie, Aronne, Shmukler, Callahan. Presented at the 2007 Obesity Society Annual Scientific Meeting. October 20 – 24, New Orleans LA

Obesity exacerbates the negative HRQL impact of cardiometabolic disease in the US. Sullivan P, Ben-Joseph R, Ghushchyan V. Presented at the 2007 13th World Congress on Heart Disease. July 28-31, Vancouver Canada

The impact of obesity on medical expenditures and productivity in individuals with cardiometabolic disease in the United States. Sullivan P, Ben-Joseph R, Ghushchyan V. Presented at the 2007 Anti-Obesity Therapies. June 13, Paris France

Correlation of weight to cardiometabolic risk as identified by icd-9 diagnosis codes and prescriptions in primary care. Brixner D, Said Q, Ghate SR. Presented at the 2007 International Society for Pharmacoeconomics and Outcomes Research. May 19-23, Arlington VA

The cost of the metabolic syndrome in the elderly: findings from the cardiovascular health study. Curtis LH, Hammill BG, Bethel MA, Anstrom KJ, Gottdiener JS, Schulman KA. Presented at the 2007 International Society for Pharmacoeconomics and Outcomes Research. May 19-23, Arlington VA

Assessment of cardiometabolic risk in a national primary care electronic medical record (EMR) database. Brixner D, Odera G, Kirkness C, Said Q. Presented at the 2007 Academy of Managed Care Pharmacy. Apr 11-14, San Diego CA

Cardiometabolic risk factor clusters represent a major economic burden to payers in the US. Presented at the 2007 Cardiovascular Disease Epidemiology and Prevention in Association with the Council on Nutrition, Physical Activity, and Metabolism. Feb 28 - Mar 3, Orlando FL

Productivity loss, employment and income associated with cardiometabolic risk factor clusters in the US. Presented at the 2006 4th Annual World Congress on the Insulin Resistance Syndrome. Oct 5-7, Las Vegas NV

Development and validation of a simple prediction model to estimate the prevalence of metabolic syndrome in populations. Presented at the 2006 American Diabetes Association. June 9-13, Washington DC

The impact of cardiovascular risk factors clusters on health-related quality of life in a nationally representative sample of US adults. Presented at the 2006 Anti-Obesity Therapies. May 18-19, Paris France

Clusters of cardiovascular risk factors: a health economic perspective for the metabolic syndrome. Presented at the 2006 American College of Cardiology. Mar 11-14, Atlanta GA

Treatment patterns of asthmatic patients in Israel according to disease severity. Presented at the 2001 American Thoracic Society Annual Meeting. May, San Francisco CA

Cost of asthma control. Presented at the 2001 American Thoracic Society Annual Meeting. May, San Francisco CA

Economic impact of tirofiban for unstable angina and non q-wave MI in the United Kingdom. Oral Presentation. Presented at the 2000 American Heart Association 73rd Scientific Sessions. New Orleans LA

Relationships between asthma control and resource consumption by asthmatic patients in Hungary. The HUNAIR study. Presented at the 2000 World Congress on Lung Health and 10th ERS Annual Congress. Florence Italy

Asthma management in Croatia. Presented at the 2000 World Congress on Lung Health and 10th ERS Annual Congress. Florence Italy

Repeat prescribing of asthma therapies in the United Kingdom. Presented at the 2000 World Congress on Lung Health and 10th ERS Annual Congress. Florence Italy

Dosing of inhaled corticosteroids for pediatric asthmatics in real world setting. An interactive model. Presented at the 2000 World Congress on Lung Health and 10th ERS Annual Congress. Florence Italy

Use of patient data in asthma outcomes research. Presented at the 2000 Sixth World Conference on Clinical Pharmacology and Therapeutics' and the 4th congress of the European Association for Clinical Pharmacology and Therapeutics (CPT). Florence Italy

Symptoms of asthma patients in Hungary considered by their physician as having good asthma control- the HUNAIR study. Presented at the 2000 EAACI meeting. Lisbon, Portugal

Economic costs of asthma management in Croatia. Presented at the 2000 EAACI meeting. Lisbon, Portugal
Adherence to asthma medications in the United Kingdom. Presented at the 2000 American Lung Association/American Thoracic Society 2000 International Conference (ALA/ATS). Toronto Canada

Pretreatment with finasteride and the blood loss during transurethral resection of the prostate. Presented at the 2000 American Urology Association 95th annual meeting. April

Changes in asthma drug therapy costs before and after the introduction of singulair in the United Kingdom. Presented at the 2000 American Academy of Allergy, Asthma & Immunology (AAAAI). San Diego CA

Dosing of inhaled corticosteroids for pediatric asthmatics in real world settings. An interactive model. Presented at the 2000 Pediatrics Pulmanology 4th International Congress. Nice France

Treatment patterns and resource utilization of pediatric asthmatics in France. Presented at the 2000 Pediatrics Pulmanology 4th International Congress. Nice France

Resource utilization of pediatric asthmatic patients in Hungary. Presented at the 2000 Pediatrics Pulmanology 4th International Congress. Nice France

Linking computerized medical files to survey data may help distinguish control from severity. Presented at the 1999 European Respiratory Society

The effect of aggrastat on hospital length of stay in patients with unstable angina or Non-Q-Wave myocardial infarction. Presented at the Cardiovascular Drug Therapy 8th International Congress

Interactive model describing compliance with inhaled asthma medications. Presented at the Asthma 99 Theory to Treatment

Control of asthma and costs of disease. Presented at the Asthma 99 Theory to Treatment

The relationships between control of asthma and direct costs. Presented at the 1999 American Thoracic Society annual meeting

Dosing of inhaled corticosteroids in clinical practice: and interactive model. Presented at the 1999 American Academy of Allergy Asthma and Immunology annual meeting

Using family practice database to study control of asthma and disease outcomes. Presented at the Joint Meeting of the French and Italian Societies of Pharmacology, March 1999

Identification of asthma in computerized family practices. Presented at the 1999 Keystone Symposium on Molecular and Cellular Biology

Assessing the burden of asthma from computerized files of french family practitioners. Presented at the 1998 World Asthma Meeting

Identification and follow-up of asthma patients in french family practices. Presented at the 1998 (XVII) Congress of the European Academy of Allergy and Clinical Immunology

Economic Implications of Long Term Effects of Finasteride on the Occurrence of Acute Urinary Retention and Surgical Interventions. Presented at the 1997 International Consultation on Benign Prostatic Hyperplasia

A cognitive approach to understanding performance monitoring in clinical Continuous Quality Improvement (CQI). Presented at the 1996 National Forum on Quality Improvement in Health Care

Cost and quality considerations in the management of patients with peptic disorders in ambulatory settings. Presented at the 1995 Excellence in Research Competition, College of Pharmacy, University of Florida

Cost, quality, and outcomes of peptic acid disorders in a managed care organizations. Presented at the University of Florida Excellence in Research Competition, Gainesville, FL, March 1995

Indicator development for a performance-based evaluation system (PBES) for community pharmacy practice. Presented at the APHA 142nd Annual Meeting, Orlando, FL, 1995

Cost of managing peptic acid disease in ambulatory setting. Presented at the 29th Annual ASHP Midyear Clinical Meeting, Miami Beach, FL, December 5, 1994 (CP-3)

Pharmacoeconomic examination of peptic acid disease. Presented at the AAPS meeting, San Diego, CA, November 8, 1994

Cost and risk considerations for patients receiving I.V. histamine2 receptor antagonists. Presented at the Southern Pharmacy Administration Conference. Gainesville, FL June 3 1994

Risk factors for adverse events among patients receiving I.V. histamine2 receptor antagonists. Presented at the University of Florida Excellence in Research Competition, Gainesville, FL, March 1994

Creating disease specific guidelines for implementing pharmaceutical care. Presented at the 28th Annual ASHP Midyear Clinical Meeting, Atlanta, GA, December 9, 1993 (IPC-08)

The realities of implementing a CQI project in an inpatient setting. Presented at the 28th Annual ASHP Midyear Clinical Meeting, Atlanta, GA, December 7, 1993 (P-189D)

Risk for adverse events among patients receiving I.V. histamine2 receptor antagonists. Presented at the 1993 Excellence in Research Competition, College of Pharmacy, University of Florida

Evaluation of a drug use evaluation data collection instrument. Presented at the 27th Annual ASHP Midyear Clinical Meeting, Orlando, FL, December 10, 1992

Cost analysis of intravenous histamine2 receptor antagonists. Presented at the 1992 Excellence in Research Competition, College of Pharmacy, University of Florida

Multi-center drug use evaluation and cost analysis of intravenous histamine2 receptor antagonists. Presented at the 26th Annual ASHP Midyear Clinical Meeting, New Orleans, LA, December 10, 1991